| Similar Articles |
|---|
 |
The Motley Fool
July 28, 2010
Brian Orelli |
Now There's an Illuminating Idea Helping your customers sell more of your product makes a lot of sense.   |
The Motley Fool
April 27, 2011
Brian Orelli |
Illuminating the Growth Competition in the DNA sequencing market may be heating up, but 47% growth for Illumina isn't too shabby. |
The Motley Fool
July 22, 2009
Brian Orelli |
Levering the Genome Lower revenue can't stop Illumina from turning in a good bottom line. |
The Motley Fool
April 22, 2009
Brian Orelli |
Illuminating Stock Option Problems Illumina's stock options are getting a little ridiculous. This problem was pointed out in the third quarter last year, and it doesn't seem to be going away. |
The Motley Fool
October 28, 2009
Brian Orelli |
Ugly, but Still Built for Growth It continues to be a tale of two business segments for Illumina, with sales from the consumables used in its sequencing machines more than doubling, while its array business remains down considerably. |
The Motley Fool
February 6, 2008
Brian Orelli |
Insatiable Illumina Revenue is way up at Illumina, but can the company keep it going looking forward? |
The Motley Fool
April 24, 2008
Brian Orelli |
Illumina Ignites This biochip maker is on fire. |
The Motley Fool
October 22, 2008
Jim Mueller |
Illuminating Illumina Did the DNA analysis equipment maker miss, meet, or beat expectations? Well, it's complicated. |
The Motley Fool
July 24, 2008
Brian Orelli |
Illumina Polishes Its Biochips There's very little to complain about in Illumina's earnings report. In this market, you'll see few investors grumbling about double-digit growth. |
The Motley Fool
October 24, 2008
Brian Orelli |
Affymetrix Has Trouble Turning Around The problem is that Affymetrix doesn't sell sequencers, and no one seems to want the genome and RNA analyzers that it does sell. |
The Motley Fool
February 8, 2010
Brian Orelli |
An Earnings Surprise of an Unusual Kind Illumina beats management's own preliminary revenue announcement. |
The Motley Fool
January 11, 2008
Brian Orelli |
Biochip Packaging: Some Settling May Occur Biochip maker Illumina settles its disputes about patents with Affymetrix. |
The Motley Fool
August 6, 2008
Brian Orelli |
Illumina Grabs Some Cash With biochip maker Illumina hitting 52-week highs, it seems inevitable that the company would do a secondary offering to grab some cash -- about $300 million, as it turns out. |
The Motley Fool
October 24, 2007
Brian Orelli |
Illumina's Illuminating Results There was stellar revenue growth, but margins and stock compensations pulled the bottom line down. |
The Motley Fool
February 8, 2011
Brian Orelli |
What Will Intuitive Surgical Do for an Encore? Intuitive Surgical managed just a 10% year-over-year increase in revenue from sales of its da Vinci Surgical Systems in the fourth quarter of last year. Yet its total revenue increased a solid 21%. How? |
The Motley Fool
October 28, 2009
Brian Orelli |
The Waters Aren't Flowing. Yet. Not unlike its products that turn ugly mixtures into purer products, Waters turned an ugly top line into an acceptable earnings growth in the third quarter. |
The Motley Fool
July 25, 2007
Brian Orelli |
Shiny Happy Illumina Illumina, which makes chips that can distinguish one million different genes, announced another stellar quarter. That makes eight in a row. |
The Motley Fool
August 16, 2007
Brian Orelli |
More Drugmaker Growth Without the FDA All that high-tech lab equipment has to come from somewhere. Here's how investors can benefit from it, too. |
The Motley Fool
August 25, 2009
Brian Orelli |
That's How You Want to Spend Investors' Money? A high-growth buyback? Really? On the surface, the buyback of Illumina shares looks like a pretty poor use of capital, but in truth, the move might not be that bad for investors. |
Chemistry World
May 29, 2014
Hepeng Jia |
Chinese-made DNA sequencer aims to challenge foreign dominance With an independently developed next-generation DNA sequencer, Chinese scientists are aiming to challenge the dominance of international players in the world's fastest growing genome sequencing market. |
Chemistry World
April 19, 2013
Sarah Houlton |
Thermo Fisher to buy Life Technologies in $15.8bn deal Life Technologies specializes in research products, with a particular focus on genetic sequencing and DNA analysis. |
The Motley Fool
January 14, 2010
Brian Orelli |
$1,000 Genomes, Here We Come Illumina jumps on news of its $10,000 genome. |
The Motley Fool
November 12, 2008
Brian Orelli |
Affymetrix Gets Specific The biochip maker announces that it will acquire privately held Panomics for $73 million in cash. |
The Motley Fool
October 25, 2007
Brian Orelli |
Turnaround at Affymetrix Affymetrix announces it is continuing its turnaround from an abysmal 2006 with another strong quarter. |
The Motley Fool
April 27, 2007
Brian Orelli |
Making Money Off Your Competitors Affymetrix is looking appealing with a few new products and potential revenues from an unlikely source. Investors, take note. |
BusinessWeek
February 20, 2006
Gene G. Marcial |
Fast Growth At Illumina Is In The Genes The company has become a rising star in the complex analysis of gene variation, and the stock shows it. |
Chemistry World
January 8, 2013
Andrew Turley |
Illumina investment push Gene sequencing company Illumina has struck a $450 million deal to buy privately owned US firm Verinata Health, which specializes in non-invasive tests for early identification of fetal chromosomal abnormalities. |
The Motley Fool
October 26, 2011
Tim Beyers |
Thermo Fisher Scientific Shares Plunged: What You Need to Know Shares of Thermo Fisher Scientific fell more than 10% in early trading and closed off almost that much after lowering full-year earnings and revenue guidance. |
The Motley Fool
April 25, 2008
Brian Orelli |
Affymetrix Learns About Inertia Slower sales of its older chips drag down growth. |
The Motley Fool
May 26, 2011
Andrew Tonner |
Does Agilent Technologies Deserve a Spot in Your Portfolio? Let's take a look at Agilent Technologies and some of its closest peers. |
The Motley Fool
June 5, 2008
Brian Orelli |
Test Results Boost Sequenom's Stock They are early results, but the Down syndrome tests could bring big changes to the industry. |
The Motley Fool
August 12, 2009
Brian Orelli |
The Next Big Thing Is Not Right in Front of You Perhaps the fastest evolving technology right now is found in DNA sequencing. |
Chemistry World
November 21, 2013
Phillip Broadwith |
Rapid DNA sequencing cleared for the clinic The approval covers Illumina's MiSeqDx instrument, together with two diagnostic assay kits for cystic fibrosis that run on it, and a kit that allows clinical labs to develop their own diagnostic tests. |
Bio-IT World
February 2007
Robert M. Frederickson |
Scramble for CodeLink Customers GE Healthcare has quietly announced that it will stop production of the popular CodeLink array system in 2007. The news was not a complete surprise to some users of the system who felt the company had been backing away from the platform. |
Managed Care
September 2003 |
Primary care pay falls again Primary care physicians' compensation continues to decline, according to the American Medical Group Association's 2003 Medical Group Compensation and Productivity survey. |
The Motley Fool
August 19, 2011
Alexander Crawford |
DNA Sequencing: The Next High-Growth Market in Biotech? We compiled a list of companies with a hand in the DNA sequencing market. Should you add these companies to your watch list? |
Real Estate Portfolio
Jul/Aug 2003
James B. Wright |
Governing REIT Compensation As recent well-publicized REIT proxy/management battles have demonstrated, REIT governance issues are no longer under the radar. In time, shareholder concerns (and any REIT vulnerabilities) relative to independent compensation decisions will also receive scrutiny. |
The Motley Fool
August 15, 2011
Brian Orelli |
Another Partner, but Still No Data Sequenom signs up a European partner. |
